|Bid||128.78 x 1000|
|Ask||145.00 x 900|
|Day's Range||130.17 - 140.00|
|52 Week Range||35.00 - 141.98|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Baker Brothers Advisors raised its stake in biopharmaceutical firm Kodiak Sciences. Farallon Capital halved its investment in hotel and resort operator Playa Hotel.
Kodiak Sciences (KOD) completes recruitment in the pivotal phase IIb/III DAZZLE study, currently evaluating KSI-301 for the treatment of patients with wet age-related macular degeneration.
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.